Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712471 | 0.85 | F10 (0.43) | POLBCREBBPKDM4EBRD4ALDH1A1 | |
| SCHEMBL6791079 | 0.84 | KDM4E (0.37) | QDPRMTNR1BPOLBCREBBPKDM4E | |
| SCHEMBL5899937 | 0.83 | QDPR (0.45) | QDPRMTNR1BPOLBCREBBPKDM4E | |
| SCHEMBL5899901 | 0.82 | ENPP2 (0.46) | POLBCREBBPKDM4EBRD4ALDH1A1 | |
| SCHEMBL5937192 | 0.78 | DRD2 (0.42) | MCHR1 | |
| SCHEMBL5900137 | 0.78 | MEN1 (0.39) | MTNR1BPOLBCREBBPKDM4EBRD4 | |
| SCHEMBL5937380 | 0.78 | MEN1 (0.38) | POLBKMT2AMEN1USP2MAPT | |
| SCHEMBL5937367 | 0.76 | HTR2C (0.45) | HTR2ASLC6A3 | |
| SCHEMBL38355 | 0.75 | SIGMAR1 (0.40) | — | |
| SCHEMBL5937197 | 0.74 | SLC6A4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | QDPR 1864/4885MTNR1B 265/4885POLB 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.